VRAX (Virax Biolabs Group) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
44 GF Score
Price $3.89
GF Value $3.63
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group Other Stockholders Equity?

Virax Biolabs Group VRAX +2.64% 44 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates VRAX with a GF Score™ of 44/100 and a GF Value™ of $3.63 (Fairly Valued). The stock has 3 warning signs investors should review.

Virax Biolabs Group's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

Virax Biolabs Group's quarterly Other Stockholders Equity increased from Mar. 2025 ($-0.00 Mil) to Sep. 2025 ($0.00 Mil) but then declined from Sep. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Virax Biolabs Group's annual Other Stockholders Equity declined from Mar. 2024 ($-0.00 Mil) to Mar. 2025 ($-0.00 Mil) but then stayed the same from Mar. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Virax Biolabs Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group Other Stockholders Equity Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial -0.00 -0.00 -0.00 -0.00 -0.00

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 0.00 -0.00
VRAX
44GF Score
Virax Biolabs Group Ltd VRAX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Virax Biolabs Group (VRAX) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Other Stockholders Equity too high?
Virax Biolabs Group's current Other Stockholders Equity is $-0.00 Mil. Overall, Virax Biolabs Group has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Other Stockholders Equity compare to BBLG and PKTX?
Virax Biolabs Group's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.63, compared to a current price of $3.89 — trading 7.2% above its estimated fair value. The current Other Stockholders Equity is $-0.00 Mil. Virax Biolabs Group's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.89 is trading 7.2% above its estimated GF Value™ of $3.63. GuruFocus considers Virax Biolabs Group to be Fairly Valued.

Key valuation signals for VRAX:

  • Other Stockholders Equity: $-0.00 Mil
  • GF Value™: $3.63 vs. price of $3.89 (7.2% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score

Get the complete analysis for VRAX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.89
Price
$3.63
GF Value